| BioCryst Pharmaceuticals, Inc. | |
|---|---|
| Type | Public |
| Nasdaq: BCRX Russell 2000 Component | |
| Industry | Healthcare |
| Founded | 1986 |
| Headquarters | Durham, North Carolina, US |
| Key people | Charlie Gayer (president and CEO) |
| Products | ORLADEYO, RAPIVAB |
| Revenue | |
Number of employees | 450 |
| Website | www.biocryst.com |
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
This section needs to be updated. (May 2021) |
BioCryst’s core development programs include: